Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Trial Details

NCT ID

NCT05573126

Phase

PHASE1 / PHASE2

Sponsor

Ellipses Pharma

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• EP0062
• Elacestrant
• Everolimus
• Abemaciclib
• Fulvestrant
• Exemestane

Locations (sample)

• New Haven, Connecticut, United States|41.30815,-72.92816
• Tampa, Florida, United States|27.94752,-82.45843
• Boston, Massachusetts, United States|42.35843,-71.05977
• Detroit, Michigan, United States|42.33143,-83.04575
• Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

• Women 18 years or older at the time of informed consent
• Histologically proven diagnosis of breast cancer with evidence of metastatic or locally advanced breast adenocarcinoma as defined by the American J…
• Availability of archival tumour sample (formalin-fixed, paraffin-embedded block(s) or slides from a primary tumour or biopsy of a metastatic tumour…
• Biopsy-proven AR+ and ER+ breast cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.